Core Viewpoint - Baiyang Pharmaceutical experienced a decline of 0.79% in stock price on November 14, with a trading volume of 101 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On November 14, Baiyang Pharmaceutical had a financing buy-in amount of 8.01 million yuan and a financing repayment of 12.08 million yuan, resulting in a net financing outflow of 4.07 million yuan [1]. - The total financing and securities balance for Baiyang Pharmaceutical reached 485 million yuan, with the financing balance accounting for 3.84% of the circulating market value, indicating a high level compared to the past year [1]. - The company had a securities lending repayment of 200 shares on November 14, with no shares sold, and a remaining securities lending balance of 36,700 shares valued at 880,100 yuan, also reflecting a high level compared to the past year [1]. Business Performance - As of September 30, Baiyang Pharmaceutical reported a total of 11,100 shareholders, a decrease of 40.83% from the previous period, while the average circulating shares per person increased by 68.99% to 47,194 shares [2]. - For the period from January to September 2025, Baiyang Pharmaceutical achieved operating revenue of 5.63 billion yuan, a year-on-year decrease of 8.41%, and a net profit attributable to shareholders of 476 million yuan, down 25.67% year-on-year [2]. Dividend Information - Since its A-share listing, Baiyang Pharmaceutical has distributed a total of 1.55 billion yuan in dividends, with 1.20 billion yuan distributed over the past three years [3]. - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited as the newest shareholder, holding 2.91 million shares, while ICBC Frontier Medical Stock A exited the top ten list [3].
百洋医药11月14日获融资买入801.39万元，融资余额4.84亿元